IL155278A0 - Pyridinone derivatives for treatment of atherosclerosis - Google Patents
Pyridinone derivatives for treatment of atherosclerosisInfo
- Publication number
- IL155278A0 IL155278A0 IL15527801A IL15527801A IL155278A0 IL 155278 A0 IL155278 A0 IL 155278A0 IL 15527801 A IL15527801 A IL 15527801A IL 15527801 A IL15527801 A IL 15527801A IL 155278 A0 IL155278 A0 IL 155278A0
- Authority
- IL
- Israel
- Prior art keywords
- atherosclerosis
- treatment
- pyridinone derivatives
- pyridinone
- derivatives
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 150000005299 pyridinones Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Materials Engineering (AREA)
- Rheumatology (AREA)
- Structural Engineering (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0024808.8A GB0024808D0 (en) | 2000-10-10 | 2000-10-10 | Novel compounds |
| PCT/EP2001/011610 WO2002030904A1 (en) | 2000-10-10 | 2001-10-05 | Pyridinone derivatives for treatment of atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL155278A0 true IL155278A0 (en) | 2003-11-23 |
Family
ID=9901006
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15527801A IL155278A0 (en) | 2000-10-10 | 2001-10-05 | Pyridinone derivatives for treatment of atherosclerosis |
| IL155278A IL155278A (en) | 2000-10-10 | 2003-04-08 | Compressed Pyridine-4-On and Pyridine-4-On Derivatives |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL155278A IL155278A (en) | 2000-10-10 | 2003-04-08 | Compressed Pyridine-4-On and Pyridine-4-On Derivatives |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20040063753A1 (de) |
| EP (2) | EP2258688B1 (de) |
| JP (1) | JP4212354B2 (de) |
| KR (1) | KR100824134B1 (de) |
| CN (2) | CN1951917B (de) |
| AR (1) | AR035349A1 (de) |
| AT (1) | ATE538096T1 (de) |
| AU (2) | AU1052402A (de) |
| BR (1) | BRPI0114576B1 (de) |
| CA (1) | CA2425268C (de) |
| CY (2) | CY1112442T1 (de) |
| CZ (1) | CZ304558B6 (de) |
| DK (2) | DK1326841T3 (de) |
| ES (2) | ES2378059T3 (de) |
| GB (1) | GB0024808D0 (de) |
| GC (1) | GC0000307A (de) |
| HU (1) | HU230767B1 (de) |
| IL (2) | IL155278A0 (de) |
| MX (1) | MXPA03003176A (de) |
| MY (1) | MY135766A (de) |
| NO (1) | NO325107B1 (de) |
| NZ (1) | NZ525225A (de) |
| PL (1) | PL207560B1 (de) |
| PT (2) | PT2258688E (de) |
| SI (2) | SI1326841T1 (de) |
| TW (1) | TWI293293B (de) |
| WO (1) | WO2002030904A1 (de) |
| ZA (1) | ZA200302785B (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1263740T3 (da) * | 2000-02-16 | 2006-11-13 | Smithkline Beecham Plc | Pyrimidin-4-on-derivat som LDL-PLA2-inhibitor |
| GB0119793D0 (en) * | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
| GB0127139D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127140D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0208279D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| US7741020B2 (en) | 2004-04-16 | 2010-06-22 | Glaxo Group Limited | Methods for detecting Lp-PLA2 activity and inhibition of Lp-PLA2 activity |
| US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| US20080090851A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| US20080090852A1 (en) * | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| US7705005B2 (en) * | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
| CN101687009A (zh) * | 2007-05-11 | 2010-03-31 | 宾夕法尼亚大学理事会 | 治疗皮肤溃疡的方法 |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| KR101730290B1 (ko) | 2007-05-11 | 2017-04-25 | 토마스 제퍼슨 유니버시티 | 신경변성 질환 및 장애의 치료 및 예방 방법 |
| US9512104B2 (en) | 2009-07-28 | 2016-12-06 | Auspex Pharmaceuticals, Inc. | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
| US8575348B2 (en) | 2009-07-28 | 2013-11-05 | Auspex Pharmaceuticals, Inc | Quinolone inhibitors of lipoprotein-associated phospholipase A2 |
| WO2011049722A1 (en) * | 2009-10-19 | 2011-04-28 | Merck Sharp & Dohme Corp. | PYRAZOLO [3,4-b] PYRIDIN-4-ONE KINASE INHIBITORS |
| EP2583099B1 (de) | 2010-06-18 | 2016-11-02 | Whitehead Institute for Biomedical Research | Pla2g16 als target für antivirusverbindungen |
| KR101861883B1 (ko) * | 2010-12-06 | 2018-05-28 | 글락소 그룹 리미티드 | Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물 |
| JP2013544854A (ja) * | 2010-12-06 | 2013-12-19 | グラクソ グループ リミテッド | 化合物 |
| ES2847883T3 (es) | 2010-12-17 | 2021-08-04 | Glaxo Group Ltd | Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares |
| WO2013000108A1 (zh) * | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | 唑类杂环化合物、其制备方法、药物组合物和用途 |
| AR087309A1 (es) | 2011-07-27 | 2014-03-12 | Glaxo Group Ltd | Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis |
| CA2842965A1 (en) | 2011-07-27 | 2013-01-31 | Glaxo Group Limited | 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors |
| LT2751094T (lt) | 2011-09-01 | 2018-11-12 | Glaxo Group Limited | Naujoji kristalinė forma |
| MX2015009633A (es) | 2013-01-25 | 2015-11-30 | Glaxosmithkline Ip Dev Ltd | Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona. |
| US9296755B2 (en) | 2013-01-25 | 2016-03-29 | Glaxosmithkline Intellectual Property Development Limited | 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds and their therapeutic applications |
| EP2948456A4 (de) | 2013-01-25 | 2016-09-14 | Glaxosmithkline Ip Dev Ltd | Bicyclische pyrimidonverbindungen als lp-pla2-hemmer |
| EP2764866A1 (de) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Hemmer der nedd8-aktivierenden Enzyme |
| US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
| WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| CN104840963B (zh) * | 2015-05-26 | 2018-02-16 | 河北东康生物科技有限公司 | 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用 |
| WO2016198691A1 (en) | 2015-06-11 | 2016-12-15 | Basilea Pharmaceutica Ag | Efflux-pump inhibitors and therapeutic uses thereof |
| CN112574221B (zh) * | 2019-09-30 | 2022-03-04 | 上海纽思克生物科技有限公司 | 四环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| EP4056571A4 (de) | 2019-11-09 | 2024-01-24 | Shanghai Simr Biotechnology Co., Ltd. | Trizyklisches dihydroimidazopyrimidonderivat, verfahren zu seiner herstellung, pharmazeutische zusammensetzung und verwendung davon |
| CN112510260B (zh) * | 2020-11-27 | 2022-11-04 | 珠海市赛纬电子材料股份有限公司 | 电解液添加剂、非水电解液和锂离子电池 |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| WO2025015951A1 (zh) | 2023-07-17 | 2025-01-23 | 上海枢境生物科技有限公司 | 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5769527A (en) | 1986-07-17 | 1998-06-23 | Vari-Lite, Inc. | Computer controlled lighting system with distributed control resources |
| US5585246A (en) | 1993-02-17 | 1996-12-17 | Biometric Imaging, Inc. | Method for preparing a sample in a scan capillary for immunofluorescent interrogation |
| EP0658205B1 (de) | 1993-06-25 | 2000-03-15 | Smithkline Beecham Plc | An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie |
| ATE315655T1 (de) | 1993-10-06 | 2006-02-15 | Icos Corp | Acethylhydrolase des plättchen aktivierenden faktors |
| GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| HUT77089A (hu) | 1994-12-22 | 1998-03-02 | Smithkline Beecham Plc. | Atherosclerosis kezelésére alkalmas szubsztituált 2-oxo-azetidinek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
| CN1197452A (zh) | 1995-07-01 | 1998-10-28 | 史密丝克莱恩比彻姆有限公司 | 用于治疗动脉粥样硬化的氮杂环丁烷酮衍生物 |
| FR2743912B1 (fr) | 1996-01-24 | 1998-04-10 | Matra Communication | Circuit de resolution d'equation-cle et decodeur reed-solomon incorporant un tel circuit |
| US5684794A (en) | 1996-01-25 | 1997-11-04 | Hazeltine Corporation | Validation of subscriber signals in a cellular radio network |
| GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| HUP0001140A3 (en) * | 1996-12-05 | 2002-05-28 | Amgen Inc Thousand Oaks | Substituted pyrimidinone and pyridone compounds and methods of use |
| GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| ES2203988T3 (es) * | 1997-11-06 | 2004-04-16 | Smithkline Beecham Plc | Compuestos de pirimidinona y composiciones farmaceuticas que los contienen. |
| WO2000010980A1 (en) | 1998-08-21 | 2000-03-02 | Smithkline Beecham Plc | Pyrimidinone derivatives for the treatment of atherosclerosis |
| GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| KR20020012200A (ko) | 1999-05-01 | 2002-02-15 | 피터 기딩스 | 피리미디논 화합물 |
| GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
-
2000
- 2000-10-10 GB GBGB0024808.8A patent/GB0024808D0/en not_active Ceased
-
2001
- 2001-10-05 AU AU1052402A patent/AU1052402A/xx active Pending
- 2001-10-05 CN CN200610128890XA patent/CN1951917B/zh not_active Expired - Fee Related
- 2001-10-05 IL IL15527801A patent/IL155278A0/xx unknown
- 2001-10-05 ES ES01978400T patent/ES2378059T3/es not_active Expired - Lifetime
- 2001-10-05 SI SI200131008T patent/SI1326841T1/sl unknown
- 2001-10-05 EP EP10177773A patent/EP2258688B1/de not_active Expired - Lifetime
- 2001-10-05 EP EP01978400A patent/EP1326841B1/de not_active Expired - Lifetime
- 2001-10-05 CN CNB018201253A patent/CN1280275C/zh not_active Expired - Fee Related
- 2001-10-05 KR KR1020037005084A patent/KR100824134B1/ko not_active Expired - Fee Related
- 2001-10-05 AT AT01978400T patent/ATE538096T1/de active
- 2001-10-05 JP JP2002534290A patent/JP4212354B2/ja not_active Expired - Fee Related
- 2001-10-05 DK DK01978400.8T patent/DK1326841T3/da active
- 2001-10-05 PT PT101777738T patent/PT2258688E/pt unknown
- 2001-10-05 MX MXPA03003176A patent/MXPA03003176A/es active IP Right Grant
- 2001-10-05 HU HU0302480A patent/HU230767B1/hu not_active IP Right Cessation
- 2001-10-05 CZ CZ2003-1009A patent/CZ304558B6/cs not_active IP Right Cessation
- 2001-10-05 US US10/399,022 patent/US20040063753A1/en not_active Abandoned
- 2001-10-05 SI SI200131019T patent/SI2258688T1/sl unknown
- 2001-10-05 PL PL366334A patent/PL207560B1/pl unknown
- 2001-10-05 CA CA2425268A patent/CA2425268C/en not_active Expired - Fee Related
- 2001-10-05 NZ NZ525225A patent/NZ525225A/en not_active IP Right Cessation
- 2001-10-05 AU AU2002210524A patent/AU2002210524B2/en not_active Ceased
- 2001-10-05 BR BRPI0114576A patent/BRPI0114576B1/pt not_active IP Right Cessation
- 2001-10-05 WO PCT/EP2001/011610 patent/WO2002030904A1/en not_active Ceased
- 2001-10-05 ES ES10177773T patent/ES2399325T3/es not_active Expired - Lifetime
- 2001-10-05 PT PT01978400T patent/PT1326841E/pt unknown
- 2001-10-05 DK DK10177773.8T patent/DK2258688T3/da active
- 2001-10-08 GC GCP20011661 patent/GC0000307A/en active
- 2001-10-08 MY MYPI20014669A patent/MY135766A/en unknown
- 2001-10-08 TW TW090124779A patent/TWI293293B/zh not_active IP Right Cessation
- 2001-10-10 AR ARP010104760A patent/AR035349A1/es active IP Right Grant
-
2003
- 2003-04-08 IL IL155278A patent/IL155278A/en not_active IP Right Cessation
- 2003-04-09 NO NO20031626A patent/NO325107B1/no not_active IP Right Cessation
- 2003-04-09 ZA ZA200302785A patent/ZA200302785B/en unknown
-
2004
- 2004-07-28 US US10/900,489 patent/US7235566B2/en not_active Expired - Lifetime
-
2012
- 2012-03-07 CY CY20121100228T patent/CY1112442T1/el unknown
-
2013
- 2013-02-08 CY CY20131100118T patent/CY1113648T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1052402A (en) | Pyridinone derivatives for treatment of atherosclerosis | |
| IL213240A0 (en) | Method of treatment using lighnd-immunogen conjugates | |
| GB0014969D0 (en) | Novel method of treatment | |
| PL342076A1 (en) | Method of treating surfaces | |
| AU2001286983A1 (en) | Method of treatment | |
| AU7845701A (en) | Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals | |
| IL152810A0 (en) | Novel polymorph v of torasemide | |
| IL153424A0 (en) | Process for the preparation of quinoline derivatives | |
| GB2380481B (en) | Means for treatment of atherosclerosis | |
| GB0008921D0 (en) | Method of treatment | |
| HUP0301027A3 (en) | Process for the extraction of 2-hydroxy pyridine 2-hydroxyquinoline and 2-hydroxybenzothiazole derivatives | |
| EP1359912A4 (de) | Neue verfahren zur anwendung von pyridinderivaten | |
| EP1303281A4 (de) | Verfahren zur behandlung | |
| AU6789501A (en) | Method of dusting-preventive treatment of powder having dusting property | |
| PL343942A1 (en) | Novel derivative of isothiazole pyridine | |
| GB0002762D0 (en) | Method of treatment | |
| PL340617A1 (en) | Derivatives of 2-acylpyridine | |
| PL341634A1 (en) | Method of obtaining derivatives of phenylsulphonylmethyltetrazole | |
| HK1052861A (en) | Vaccine for the treatment of atherosclerosis | |
| GB0026742D0 (en) | Novel method of treatment | |
| AUPR213000A0 (en) | Method of treatment | |
| AUPQ662500A0 (en) | Method of treatment | |
| AUPQ949500A0 (en) | Method of treatment | |
| GB0013928D0 (en) | Methods of treatment | |
| GB0014904D0 (en) | Methods of treatment |